Construction of a Cuproptosis-Related lncRNA Prognostic Model for Bladder Urothelial Carcinoma and Screening of Potential Drugs

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">ID</td><td class="align_center">Coefficient</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">CASC20</td><td class="align_center">0.686828262</td></tr><tr><td class="align_left">‘SCAMP1-AS1’</td><td class="align_center">−0.910543962</td></tr><tr><td class="align_left">AC108066.2</td><td class="align_center">−1.920725726</td></tr><tr><td class="align_left">AC110611.1</td><td class="align_center">−2.506788801</td></tr><tr><td class="align_left">‘NR2F2-AS1’</td><td class="align_center">3.872755402</td></tr><tr><td class="align_left">AC022165.1</td><td class="align_center">−1.145970684</td></tr><tr><td class="align_left">MIR181A2HG</td><td class="align_center">−0.342648292</td></tr><tr><td class="align_left">AC010132.4</td><td class="align_center">−1.908268477</td></tr><tr><td class="align_left">AC124283.3</td><td class="align_center">1.504962992</td></tr><tr><td class="align_left">AP000593.3</td><td class="align_center">0.340927746</td></tr><tr><td class="align_left">AC078778.1</td><td class="align_center">1.373238179</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Multivariate Cox analysis of lncRNA associated with cuproptosis.</div>

Analytical Cellular Pathology

tab2

Table 2

Table 2: Construction of a Cuproptosis-Related lncRNA Prognostic Model for Bladder Urothelial Carcinoma and Screening of Potential Drugs 